Recent Updates
Recently added Catalysts
ESLA Positive Sentiment Score: 65/100

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination New York

Key Takeaway: TradeUP Acquisition Corp. announced an extension of the deadline for its initial business combination from April 19, 2023, to May 19, 2023. This extension comes with a deposit of $45,511 made into its trust account for each public share not redeemed by stockholders. TradeUP is merging with Estrella Biopharma, a company specializing in developing therapies for blood cancers and solid tumors. The announcement also noted that further details about the transaction will be filed with the SEC, highlighting pending regulatory steps before finalizing the merger.

Market Sentiment Analysis

POSITIVE FACTORS

  • TradeUP Acquisition Corp. successfully extended the deadline for its initial business combination, showing proactive management.
  • The company has a financial backing with a significant deposit of $45,511 to support the extension.
  • Estrella Biopharma is progressing in developing innovative therapies for blood cancers and solid tumors, indicating a strong future potential.

CONCERNS & RISKS

  • The extension of the deadline may indicate potential delays in the business combination process, raising concerns among stakeholders.
  • There are inherent uncertainties regarding the completion of the merger, including the need for stockholder approval and meeting other closing conditions.

Full Press Release Details

TradeUP Acquisition Corp. Announces
Extension of the Deadline for an Initial Business
New York, April 13, 2023 /PRNewswire/ - TradeUP
Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ: UPTD) today announced that, in order to extend the date
by which the Company must complete its initial business combination from April 19, 2023 to May 19, 2023, for each public share that is
not redeemed by the Company's stockholders in connection with such extension (collectively, the "Remaining Shares",
each, a "Remaining Share"), the Company has deposited into its trust account (the "Trust Account") an aggregate
of $45,511.00 (the "Monthly Extension Fee"), representing $0.05 per public share of the Company.
The payment for such Monthly Extension Fee was made
by Estrella Biopharma, Inc., a Delaware corporation ("Estrella"), pursuant to the Agreement and Plan of Merger (the "Merger
Agreement"), entered by and among the Company, Tradeup Merger Sub Inc., a Delaware corporation and direct and wholly owned subsidiary
of UPTD ("Merger Sub"), and Estrella on September 30, 2022.
Pursuant to the Company's current Charter, the
Company may extend on monthly basis from January 19, 2023 until July 19, 2023 or such an earlier date as may be determined by its board
to complete a business combination by depositing the Monthly Extension Fee for each month into the Trust Account.
TradeUP Acquisition Corp. is a blank check company
formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business
combination with one or more businesses. TradeUP was incorporated under the laws of the State of Delaware on January 6, 2021.
Estrella, a Delaware corporation, is a preclinical-stage
biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment
challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human
immune system to transform the lives of patients fighting cancer.
Important Additional Information Regarding the
Transaction Will Be Filed With the SEC
TradeUP has filed with the SEC a registration statement
on Form S-4 (File No.: 333-267918) (the "Form S-4") containing a preliminary proxy statement and a preliminary prospectus
of TradeUP containing information about the proposed business combination and the respective businesses of TradeUP and Estrella, initially
filed on October 18, 2022 and as amended from time to time, and after the proxy statement/prospectus is declared effective, TradeUP will
mail a definitive proxy statement/prospectus relating to the proposed business combination to its stockholders and Estrella's shareholders.
This press release does not contain all the information that should be considered concerning the proposed business combination and is
not intended to form the basis of any investment decision or any other decision in respect of the business combination. TradeUP's
stockholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments
thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed business combination,
as these materials will contain important information about Estrella, TradeUP and the proposed business combination. When available, the
definitive proxy statement/prospectus and other relevant materials for the proposed business combination will be mailed to stockholders
of TradeUP as of a record date to be established for voting on the proposed business combination. Such stockholders will also be able
to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with
the SEC, without charge, once available, at the SEC's website at www.sec.gov, or by directing a request to TradeUP Acquisition Corp.,
437 Madison Avenue, 27th Floor, New York, New York 10022, and its telephone number is (732) 910-9692, Attention: Jianwei Li, Co-Chief
Forward-Looking Statements
This press release contains forward-looking statements
within the meaning of section 27A of the U.S. Securities Act of 1933, as amended (the "Securities Act"), and section 21E of
the U.S. Securities Exchange Act of 1934 ("Exchange Act") that are based on beliefs and assumptions and on information currently
available to TradeUP and Estrella. In some cases, you can identify forward-looking statements by the following words: "may,"
"will," "could," "would," "should," "expect," "intend," "plan,"
"anticipate," "believe," "estimate," "predict," "project," "potential,"
"continue," "ongoing," "target," "seek" or the negative or plural of these words, or other
similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these
words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including
projections of market opportunity and market share, the capability of Estrella's business plans including its plans to expand, the
sources and uses of cash from the proposed transaction, the anticipated enterprise value of the combined company following the consummation
of the proposed transaction, any benefits of Estrella's partnerships, strategies or plans as they relate to the proposed transaction,
anticipated benefits of the proposed transaction and expectations related to the terms and timing of the proposed transaction are also
forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity,
performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Although each
of TradeUP and Estrella believes that it has a reasonable basis for each forward-looking statement contained in this communication, each
of TradeUP and Estrella caution you that these statements are based on a combination of facts and factors currently known and projections
of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the proxy statement/prospectus
on Form S-4 relating to the proposed transaction and other documents filed by TradeUP or Estrella from time to time with the SEC. These
filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially
from those contained in the forward-looking statements. Neither TradeUP nor Estrella can assure you that the forward-looking statements
in this communication will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties,
including, among others, the ability to complete the business combination due to the failure to obtain approval from TradeUP's stockholders
or satisfy other closing conditions in the business combination agreement, the occurrence of any event that could give rise to the termination
of the business combination agreement, the ability to recognize the anticipated benefits of the business combination, the amount of redemption
requests made by TradeUP's public stockholders, costs related to the transaction, the impact of the global COVID-19 pandemic, the
risk that the transaction disrupts current plans and operations as a result of the announcement and consummation of the transaction, the
outcome of any potential litigation, government or regulatory proceedings and other risks and uncertainties, including those to be included
under the heading "Risk Factors" in the Form S-4, as amended from time to time, the final
prospectus for TradeUP's initial public offering filed with the SEC on June 19, 2021,
its Annual Report on Form 10-K and in its subsequent quarterly reports on Form 10-Q and other filings with the SEC. There may be
additional risks that neither TradeUP or Estrella presently know or that TradeUP and Estrella currently believe are immaterial that could
also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties
in these forward-looking statements, you should not regard these statements as a representation or warranty by TradeUP, Estrella, their
respective directors, officers or employees or any other person that TradeUP and Estrella will achieve their objectives and plans in any
specified time frame, or at all. The forward-looking statements in this press release represent the views of TradeUP and Estrella as of
the date of this communication. Subsequent events and developments may cause those views to change. However, while TradeUP and Estrella
may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable
law. You should, therefore, not rely on these forward-looking statements as representing the views of TradeUP or Estrella as of any date
subsequent to the date of this communication.

Frequently Asked Questions

When has TradeUP extended its business combination deadline?

TradeUP extended its business combination deadline to May 19, 2023.

What is the Monthly Extension Fee TradeUP has deposited?

TradeUP deposited a Monthly Extension Fee of $45,511.00 into its Trust Account.

Who is responsible for the Monthly Extension Fee?

Estrella Biopharma, Inc. paid the Monthly Extension Fee on behalf of TradeUP.

What type of company is TradeUP Acquisition Corp.?

TradeUP Acquisition Corp. is a blank check company aimed at business combinations.

What is Estrella Biopharma developing?

Estrella Biopharma is developing CD19 and CD22-targeted T-cell therapies.

Last updated: Apr 13, 2023